Navigation Links
Cancer Vaccines: From First-in-Class to Best-in-Class?
Date:4/9/2013

Identifies which target strategies are new and unique from one developmental stage to the next.

3) Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.

4) Indication Selection: Shows the distribution and deployment of target strategies by cancer indications. The competitive level in each cancer indication is assessed.

5) Competitive Landscape: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:

* Head-to-head target competing analysis
* Significant drug target overlap analysis
* Cross-sectional R&D profiling of individual drug targets.
* Cross-over analysis of target strategies among different tumor types.
* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company's pipeline:
- Where are we?
- Where is our general and specific competition?
- What is the level of competition where we want to be?
* 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company's interest in the cancer vaccine pipeline by:

* Better identifying benchmarking peers
* Providing rationale for in/out licensing decisions of drug candidates
* Performing proper drug due diligence
* Strategies for commercial planning
* Guiding Research & Development efforts

Table of Contents

1 Executive Summary 3
2 About Cancer Highlights - A Module of the DevOnc Platform 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 A
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
2. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
3. Take the Skyhook Challenge and Help Beat Blood Cancer
4. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
5. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
6. Penn Medicines New Center For Personalized Diagnostics Unlocks Cancers Secrets
7. Cerulean Pharma to Present Data on CRLX101s HIF-1a Inhibition at the American Association for Cancer Research Annual Meeting
8. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
9. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
10. National Cancer Organizations Issue Joint Statement On Devastating Impact Of Sequestration
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... DUBLIN , May 27, 2015 /PRNewswire/ ... ) has announced the addition of the  ... Testing Market"  report to their offering.  ... ,This comprehensive five-country report contains 500 pages, ... current suppliers and potential market entrants identify ...
(Date:5/27/2015)... May 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity ... patients suffer from a series of diverse complications arising ... the blood or tissues, which cause a rapidly progressing ... mortality rates near 50% depending on disease severity. The ... systems of the global marketplace, which for the purposes ...
(Date:5/27/2015)... PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market ... is an autoimmune disease that permanently destroys beta cells of ... longer produce insulin. Over the last 90 years, insulin therapy ... can be offered to a patient who is newly diagnosed ... of action - long-acting as well as short or rapid-acting ...
Breaking Medicine Technology:European Hemostasis Diagnostic Testing Market Strategies 2015 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4
... CITY, Calif., July 7 Relievant Medsystems, Inc., developer ... back pain, reported today that it has completed a ... led by Morgenthaler Ventures with existing investors Canaan Partners ... participating. The company also announced that Morgenthaler partner ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ... study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin ... published on-line in Diabetologia ... in the two treatment groups. This is the longest controlled ...
Cached Medicine Technology:Relievant Medsystems Announces Completion of $20 Million Financing 2Relievant Medsystems Announces Completion of $20 Million Financing 35-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 25-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 35-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 45-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 5
(Date:5/28/2015)... The Cancer Solution: Taking Charge of Your ... and heartfelt book the Booksandauthor reviewer ever read ... for writing what should be one of the most important ... is power in action and this book has both. , ... talk about and unfortunately many persons know little about it. ...
(Date:5/28/2015)... 2015 The 110-mile April 24-26 ... from national non-profit World T.E.A.M. Sports is featured in ... With Heroes . , Host Bob Calvert and videographers ... and civilian riders, sponsors and staff members. The April ... a musical performance by The American Bombshells and a ...
(Date:5/27/2015)... (PRWEB) May 28, 2015 Calls Upon Individuals, ... , A new nationwide initiative – a “Summer of Service” ... create and build partnerships to grow the number of individuals ... renewing its commitment to Veterans by inviting the community to ... house June 29, 2015 from 1 – 3:00 p.m. in ...
(Date:5/27/2015)... is a reputable source of 2015 NHL Western Conference Finals ... of their series against the Anaheim Ducks with the Ducks currently ... win tonight at home, this will tie up the series with ... Center in Anaheim. , During the regular season, the Ducks ... won the Pacific Division by 8 points ahead of the second ...
(Date:5/27/2015)... Beverly Hills, CA (PRWEB) May 27, 2015 ... state of the art web portal focussed on keratoconus ... disease. This relentless progressive disease has its onset in the ... quieting down. The cornea or the front clear part of ... withstand the pressure in the eye. It results in poor ...
Breaking Medicine News(10 mins):Health News:Booksandauthor Cites The Cancer Solution as One of the Most Important Books to Read 2Health News:Videos Document World T.E.A.M. Sports' April 24-26 Face of America Bicycling Ride to Gettysburg 2Health News:Videos Document World T.E.A.M. Sports' April 24-26 Face of America Bicycling Ride to Gettysburg 3Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 2Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 3Health News:Blackhawks vs. Ducks NHL Western Conference Finals Tickets: Ticket Down Slashes Ticket Prices on Chicago Blackhawks vs. Anaheim Ducks 2015 NHL Western Conference Finals 2Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2
... for Prescription Prenatal Vitamins , , ... once-daily prescription prenatal vitamin in its category, delivering the most ... ST. LOUIS, Dec. 17 KV Pharmaceutical Company (NYSE: ... - the U.S. market leader in branded prenatal vitamins ...
... Mass., Dec. 17 Biopure Corporation (Nasdaq: ... the Food and Drug Administration (FDA) an investigational new ... 2 clinical trial of the company,s oxygen therapeutic Hemopure(R) ... trial Hemopure would be studied for use ...
... Closed the Amendment of the , -------------------------------------------------------------------- ... Notes , ------------------------------------------------- , ... BELLUS Health Inc. (NASDAQ: BLUS ; TSX: ... the NASDAQ Stock Market of its intention to voluntarily ...
... leaders pay tribute to Africa Mercy crew and commit to continue progress. ... and general Mercy Ships footage are available for download with registration at ... ... 2008 -- The Africa Mercy pulled out of the Free ...
... and B2B Marketing Pro Toby Younis today announced a free webcast ... The webcast is designed for executives in B2B companies facing challenging ... ... DC (PRWEB) December 17, 2008-- Widely recognized B2B marketing expert ...
... Physician Hospitals of America (PHA) is applauding President-elect Barack Obama,s ... Department of Health and Human Services in his Cabinet. , ... U.S. Senator from South Dakota, is both known and respected ... Falls. , , "Tom Daschle ...
Cached Medicine News:Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 2Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 3Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 4Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 5Health News:Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia 2Health News:Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia 3Health News:BELLUS Health announces formal notice to voluntarily delist from NASDAQ 2Health News:BELLUS Health announces formal notice to voluntarily delist from NASDAQ 3Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 2Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 3Health News:B2B Marketing Pro Toby Younis Announces Free Webcast on "BuzzMaking" 2Health News:Physician Hospitals of America (PHA) Applauds President-Elect Obama's Selection of Sen. Daschle as HHS Secretary 2
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... DIFF CHEK-30 is a rapid ELISA ... 100% negative predictive value and 99% sensitivity. ... and cost-effectively screen out C. difficile negatives ... of samples - before culturing for the ...
Medicine Products: